2019 UN Global Compact Communication on Progress Our Ongoing Commitment to the United Nations Global Compact We are pleased to present Amgen’s Communication on Progress to develop an antibody to potentially prevent or treat COVID-19, relating to the United Nations Global Compact. Although this update and we are also part of a broad coalition of companies and focuses on our activities during 2019, I thought it important to take government agencies, led by the National Institutes of Health, a moment to discuss the many ways Amgen is responding to the working to accelerate COVID-19 treatments and vaccines. current COVID-19 pandemic.1 Otezla® (apremilast), an oral treatment approved in more than 50 countries for inflammatory diseases such as psoriasis and • Our employees – We are providing our employees around the psoriatic arthritis, is expected to be investigated as a potential world with a wealth of resources to stay physically and mentally immunomodulatory treatment in adult patients with COVID-19 healthy and productive, whether they are working at home or in upcoming platform trials. Additionally, our deCODE Genetics continuing to come to an Amgen facility to perform missionsubsidiary has completed significant molecular epidemiology critical work. Additionally, we have expanded our staff volunteer work on SARS-CoV-2 in Iceland. program to support our employees who have medical training and wish to volunteer on the front lines of the COVID-19 • Our communities – Amgen and the Amgen Foundation pandemic. have made an initial commitment of up to $12.5 million to support COVID-19 emergency response efforts and is directing • Our patients – Amgen produces medicines that treat some of these funds toward communities globally where Amgen has the world’s most serious illnesses, including cancer and heart a significant presence, patient-focused organizations that disease. At a time when healthcare systems around the world are mounting their own response efforts and international are being stretched to their limit, we have continued to provide relief efforts by Direct Relief and International Medical Corps. an uninterrupted clinical and commercial supply of medicines Additionally, the Amgen Foundation is a proud sponsor of two for patients around the world and do not currently anticipate a online learning platforms—Khan Academy and LabXchange shortage of our medicines due to COVID-19. With respect to —that are providing free, world-class educational content to our clinical trials, study start-up activities are continuing where millions of students around the world at a time when many are operating ethically, promoting diversity in the workplace and possible to allow rapid site activation and enrollment when that no longer able to go to school. reducing our environmental footprint, to name just a few. We are becomes feasible, and study procedures are being implemented delighted to share in this Communication on Progress our recent consistent with recent guidance from regulators to maintain In 2020, Amgen celebrates the fortieth anniversary of our founding. work in these areas and many others. patient safety and study data integrity. Over the years, our most important contributions to society have come through the development of innovative medicines to treat • Our science – While infectious disease has not been an area of seriously ill patients. Our ongoing commitment to advance the focus for Amgen historically, we are leveraging our strengths in principles of the UN Global Compact reflects our dedication to Robert A. Bradway antibody engineering with our partner Adaptive Biotechnologies contributing to the greater global good in many other ways— Chairman and Chief Executive Officer 1 As of April 30, 2020. Highlights of Progress This Communication on Progress (COP) summarizes our progress offers digital instruction and virtual lab experiences to high school in the four key areas of the Global Compact principles: and college students, enabling them to gain meaningful exposure Environment, Labor, Human Rights and Anti-Corruption. Our to the scientific process. It will also include online networking commitment to serve patients drives the many Amgen programs, focused on collaboration and mentoring. procedures, policies and reporting aligned with the UNGC principles, and we continue to work to enhance our approaches Amgen entered into a strategic collaboration with BeiGene to and performance in alignment with those principles. This section expand access to Amgen oncology products in China. Cancer of the COP provides highlights of our 2019 progress and is is a leading cause of death in China, positioned to become an followed by a table that indicates where to find additional even greater public health issue as the Chinese population information about Amgen’s programs and progress that align with ages. BeiGene will commercialize three of our products in China, and we will collaborate with BeiGene to jointly develop a portion of “The LabXchange the Global Compact. our oncology portfolio in China and globally. pla�orm has helped Some of our key areas of progress in 2019 include the following: me support students with Amgen increased the number of our suppliers that we assess diverse backgrounds, so they Amgen sets ofﬁcial Guinness World Record™ for most for sustainability performance by 43 percent. We assess our can feel conﬁdent and prepared for osteoporosis screenings for an osteoporosis campaign in 24 suppliers on their sustainability performance in compliance with understanding lab experiences.” hours. The campaign took place in Brazil, Canada, Colombia, the Amgen Supplier Code of Conduct. Increasing the number of – Mary L., a biology teacher Egypt, Kuwait, Lebanon, Mexico, Saudi Arabia, South Africa and suppliers assessed improves our ability to work with our supply percentage of women in at Weston High School in Turkey with 6,056 tracked screenings on May 5, 2019. chain to improve their sustainability performance. management on a global basis Massachuse�s and, in the U.S., to increase the Amgen met and exceeded its 2020 targets for reducing Amgen and the CDC Foundation entered into a global percentage of African Americans carbon emissions and water use ahead of schedule. Our partnership to increase awareness and knowledge of and Hispanics in senior management positions. innovative use of next-generation biomanufacturing is providing cardiovascular disease (CVD) globally. With CVD recognized as significant environmental benefits. Compared with a traditional the number one cause of death worldwide, this five-year effort We continued our commitment to business ethics as one of plant, our next-generation facility in Singapore each year uses aims to expand the evidence base for CVD risk factors, with a our core values. In 2019, 100 percent of our staff trained on our approximately 268,000 less gigajoules of energy and 82,000 focus on lowand middle-income countries, by supporting the Code of Conduct, and 200+ leaders completed their Global Ethics fewer cubic meters of water, while also reducing carbon collection and analysis of data to improve understanding of the & Compliance Declaration Program, which calls for leaders in emissions by 8,800 metric tons. We are applying the same causes of CVD and interventions that may improve patient selected leadership roles to execute an ethics and compliance approach to the new manufacturing facility currently under outcomes. engagement plan and sign an annual declaration. construction in Rhode Island. We evolved and enhanced our strategy for Diversity, Inclusion Amgen continued the implementation of our collaboration The Amgen Foundation committed $11.5M to a collaboration and Belonging. At Amgen, we believe that a diverse and inclusive with the Lazarex Cancer Foundation on their IMPACT with Harvard University to create LabXchange, a new online workforce empowers us to innovate and better represent patients (IMproving Patient Access to Cancer Clinical Trials) program. community for learning, sharing and collaboration. The and are committed to an inclusive, diverse and safe workplace for This program focuses on improving clinical trial diversity for trials LabXchange platform, which launched with a focus in biology, our employees. Priorities have been established to increase the of medicines to address cancer. Summary of Relevant Reporting Amgen provides extensive reporting on policies and progress aligned with the UNGC on our website. Below is a summary table providing links to existing reporting aligned with the major categories of UNGC principles. UNGC Principles Categories Amgen Policies, Programs and Reporting Human Rights Labor Environment Anti-Corruption Responsibility Highlights Report • • • • Commitment to Corporate Social Responsibility • • • Staff Code of Conduct • • • • Diversity and Inclusion • • Access to Medicine • Staff Health and Safety • • Staff Wellness • • Environment, Health and Safety Policy • • Non-Discrimination • • Environmental Sustainability Commitment • Environmental Sustainability Performance • Amgen Foundation • Amgen Safety Net Foundation • Supplier Sustainability • • • • California Supply Chain Transparency Act • • Conflict Minerals Policy • • Conflict Minerals Report • • Supplier Diversity • • Anti-Corruption and U.S. Foreign Corrupt Practices • Interactions with Healthcare Providers • Forward-Looking Statements This communication contains forward-looking statements that developments involving current and future products, sales growth of our products, the commercialization of our product candidates, are based on the current expectations and beliefs of Amgen. All of recently launched products, competition from other products and our clinical trial operations, and any such events may have a statements, other than statements of historical fact, are statements including biosimilars, difficulties or delays in manufacturing our material adverse effect on our product development, product sales, that could be deemed forward-looking statements, including any products and global economic conditions. In addition, sales of business and results of operations. We rely on collaborations with statements on the outcome, benefits and synergies of collaborations, our products are affected by pricing pressure, political and public third parties for the development of some of our product candidates or potential collaborations, with any other company, including scrutiny and reimbursement policies imposed by third-party payers, and for the commercialization and sales of some of our commercial Adaptive Biotechnologies (including statements regarding such including governments, private insurance plans and managed care products. In addition, we compete with other companies with respect collaboration's ability to discover and develop fully-human neutralizing providers and may be affected by regulatory, clinical and guideline to many of our marketed products as well as for the discovery and antibodies targeting SARS-CoV-2 to potentially prevent or treat developments and domestic and international trends toward managed development of new products. Discovery or identification of new COVID-19), BeiGene, Ltd., or the Otezla acquisition, including care and healthcare cost containment. Furthermore, our research, product candidates or development of new indications for existing anticipated Otezla sales growth and the timing of non-GAAP EPS testing, pricing, marketing and other operations are subject to products cannot be guaranteed and movement from concept to accretion, as well as estimates of revenues, operating margins, extensive regulation by domestic and foreign government regulatory product is uncertain; consequently, there can be no guarantee capital expenditures, cash, other financial metrics, expected legal, authorities. We or others could identify safety, side effects or that any particular product candidate or development of a new arbitration, political, regulatory or clinical results or practices, manufacturing problems with our products, including our devices, indication for an existing product will be successful and become a customer and prescriber patterns or practices, reimbursement after they are on the market. Our business may be impacted by commercial product. Further, some raw materials, medical devices activities and outcomes, effects of pandemics or other widespread government investigations, litigation and product liability claims. In and component parts for our products are supplied by sole thirdhealth problems such as the ongoing COVID-19 pandemic on our addition, our business may be impacted by the adoption of new tax party suppliers. Certain of our distributors, customers and payers business, outcomes, progress, or effects relating to studies of Otezla legislation or exposure to additional tax liabilities. If we fail to meet the have substantial purchasing leverage in their dealings with us. The as a potential treatment for COVID-19, and other such estimates compliance obligations in the corporate integrity agreement between discovery of significant problems with a product similar to one of and results. Forward-looking statements involve significant risks us and the U.S. government, we could become subject to significant our products that implicate an entire class of products could have a and uncertainties, including those discussed below and more fully sanctions. Further, while we routinely obtain patents for our products material adverse effect on sales of the affected products and on our described in the Securities and Exchange Commission reports filed and technology, the protection offered by our patents and patent business and results of operations. Our efforts to collaborate with or by Amgen, including our most recent annual report on Form 10-K applications may be challenged, invalidated or circumvented by acquire other companies, products or technology, and to integrate and any subsequent periodic reports on Form 10-Q and current our competitors, or we may fail to prevail in present and future the operations of companies or to support the products or technology reports on Form 8-K. Unless otherwise noted, Amgen is providing intellectual property litigation. We perform a substantial amount of our we have acquired, may not be successful. A breakdown, cyberattack this information as of the date of this news release and does not commercial manufacturing activities at a few key facilities, including or information security breach could compromise the confidentiality, undertake any obligation to update any forward-looking statements in Puerto Rico, and also depend on third parties for a portion of our integrity and availability of our systems and our data. Our stock price contained in this document as a result of new information, future manufacturing activities, and limits on supply may constrain sales of is volatile and may be affected by a number of events. Our business events or otherwise. certain of our current products and product candidate development. performance could affect or limit the ability of our Board of Directors An outbreak of disease or similar public health threat, such as COVIDto declare a dividend or our ability to pay a dividend or repurchase our No forward-looking statement can be guaranteed and actual results 19, and the public and governmental effort to mitigate against the common stock. We may not be able to access the capital and credit may differ materially from those we project. Our results may be spread of such disease, could have a significant adverse effect on the markets on terms that are favorable to us, or at all. affected by our ability to successfully market both new and existing supply of materials for our manufacturing activities, the distribution products domestically and internationally, clinical and regulatory ®Amgen May 2020. All Rights Reserved.
